|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.
Description: Protective effect against COVID 19, after 14 days following the full course of vaccination among healthy population aged 18 years old and above. Comparison of the proportions of confirmed Covid-19 cases in the two vaccine groups and the placebo group. All confirmed cases are all confirmed by DSMB blind examination.Measure: Primary endpoint Time: One year beginning on day 14 after the second dose of immunization
Description: To evaluate the protective effect after 14 days following 2 doses of immunization of preventing severe cases of SARS CoV 2 pneumonia and deaths caused by COVID 19, among healthy population aged 18 years old and above. Comparison of the proportions of severe cases of SARS CoV 2 pneumonia and deaths in the two vaccine groups and the placebo group.Measure: Secondary endpoint Time: One year beginning on day 14 after the second dose of immunization
Description: Observe the incidence of any adverse reactions/events within 30 minutes after each dose of vaccine Observe the incidence of adverse reactions/events at 0 ~ 7 days and 8 ~ 21/30 days after each dose of vaccine. Observe the incidence of serious adverse events (SAE) from the beginning of the first dose to 6 months after the whole course of immunization.Measure: Safety endpoints Time: 6 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports